Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | PGR | P06401 | 1/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.53 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | HRH1 | P35367 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | CES2 | O00748 | 4/20 | 0.52 |
| ▸ | CES1 | P23141 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | ATM | Q13315 | 2/20 | 0.48 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.48 |
| ▸ | XBP1 | P17861 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | DAO | P14920 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL187606 | 0.83 | TDP1 (0.52) | TDP1L3MBTL1PGRADRA2AADRA2B | |
| SCHEMBL19695429 | 0.83 | TDP1 (0.52) | TDP1L3MBTL1PGRADRA2AADRA2B | |
| SCHEMBL1397470 | 0.82 | KMT2A (0.58) | TDP1L3MBTL1PGRADRA2AADRA2B | |
| SCHEMBL28283115 | 0.82 | TDP1 (0.56) | TDP1L3MBTL1PGRADRA2AADRA2B | |
| SCHEMBL163939 | 0.82 | TDP1 (0.56) | TDP1L3MBTL1PGRADRA2AADRA2B | |
| SCHEMBL13039632 | 0.82 | LMNA (0.56) | TDP1L3MBTL1PGRADRA2AADRA2B | |
| SCHEMBL15834920 | 0.80 | LMNA (0.55) | TDP1L3MBTL1PGRADRA2AADRA2B | |
| SCHEMBL12251084 | 0.80 | LMNA (0.55) | TDP1L3MBTL1PGRADRA2AADRA2B | |
| SCHEMBL1093883 | 0.80 | LMNA (0.58) | TDP1L3MBTL1PGRADRA2AADRA2B | |
| Bromide SCHEMBL8414921 | 0.80 | TDP1 (0.54) | TDP1L3MBTL1PGRADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0123441-B1 | VINCALEUKOBLASTINE DERIVATIVES | LILLY INDUSTRIES LIMITED (GB) | 1990-10-03 | — | — | EP | claimed |
| US-4675400-A | FORM CONJUGATES WITH IMMUNOGLOBULINS; ANTITUMOR AGENTS | ELI LILLY AND COMPANY (US) | 1987-06-23 | — | — | US | claimed |
| US-4596676-A | Bifunctional ester derivatives of 4-desacetyl indole-dihydroindole alkaloids | LILLY INDUSTRIES LIMITED (GB) | 1986-06-24 | — | — | US | claimed |
| EP-0123441-A1 | Vincaleukoblastine derivatives | LILLY INDUSTRIES LIMITED (GB) | 1984-10-31 | — | — | EP | claimed |
| WO-2023234187-A1 | METHOD FOR PRODUCING ORGANIC COPPER COMPOUND | シンクレスト株式会社 | 2023-12-07 | — | — | WO | disclosed |
| US-9981008-B2 | Apolipoprotein A-I mimics | CERENIS THERAPEUTICS HOLDING SA (FR) | 2018-05-29 | — | — | US | disclosed |
| EP-2939683-B1 | Apolipoprotein A-I Mimics | CERENIS THERAPEUTICS HOLDING SA (FR) | 2017-01-04 | — | — | EP | disclosed |
| US-20160324923-A1 | APOLIPOPROTEIN A-I MIMICS | CERENIS THERAPEUTICS HOLDING SA (FR) | 2016-11-10 | — | — | US | disclosed |
| US-9388232-B2 | Apolipoprotein A-I mimics | CERENIS THERAPEUTICS HOLDING SA (FR) | 2016-07-12 | — | — | US | disclosed |
| EP-2939683-A1 | Apolipoprotein A-I Mimics | Cerenis Therapeutics Holding SA (FR) | 2015-11-04 | — | — | EP | disclosed |
| EP-2396017-B1 | APOLIPOPROTEIN A-I MIMICS | CERENIS THERAPEUTICS HOLDING SA (FR) | 2015-07-01 | — | — | EP | disclosed |
| US-20150141330-A1 | APOLIPOPROTEIN A-I MIMICS | CERENIS THERAPEUTICS HOLDING SA (FR) | 2015-05-21 | — | — | US | disclosed |
| US-4533730-A | BACTERICIDES | SHIONOGI & CO., LTD. (JP) | 1985-08-06 | — | — | US | disclosed |
| US-4504659-A | 1-Oxadethiacepham compounds | SHIONOGI & CO., LTD. (JP) | 1985-03-12 | — | — | US | disclosed |
| EP-0123441-A1 | Vincaleukoblastine derivatives | LILLY INDUSTRIES LIMITED (GB) | 1984-10-31 | — | — | EP | disclosed |
| US-4478997-A | 1-Oxadethiacepham compounds | SHIONOGI & CO., LTD. (JP) | 1984-10-23 | — | — | US | disclosed |
| US-4443598-A | ANTIBIOTICS AND INTERMEDIATES | SHIONOGI & CO., LTD. (JP) | 1984-04-17 | — | — | US | disclosed |
| US-4439229-A | Substituted phthalimides herbicides | ROHM AND HAAS COMPANY (US) | 1984-03-27 | — | — | US | disclosed |
| EP-0068822-A2 | Novel heterocyclic substituted benzenes, herbicidal compositions containing them and the use thereof for combating weeds | ROHM AND HAAS COMPANY (US) | 1983-01-05 | — | — | EP | disclosed |
| US-4366316-A | FROM OXAZOLINOAZETIDINONE AND ACID | SHIONOGI & CO., LTD. (JP) | 1982-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160324923-A1 | APOLIPOPROTEIN A-I MIMICS | APOB, APOL1, LIPG | TDP1 1451/4885L3MBTL1 992/4885PGR 2597/4885 |
| US-20150141330-A1 | APOLIPOPROTEIN A-I MIMICS | APOB, APOL1, LIPG | TDP1 1451/4885L3MBTL1 992/4885PGR 2597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.